BCRX
BioCryst Pharmaceuticals, Inc.
Price Chart
Latest Quote
$8.95
+0.03 (+0.34%)
Current Price
| Previous Close | $8.92 |
| Open | $8.95 |
| Day High | $9.18 |
| Day Low | $8.82 |
| Volume | 4,450,575 |
Stock Information
| Shares Outstanding | 254.16M |
| Total Debt | $858.08M |
| Cash Equivalents | $238.40M |
| Revenue | $885.72M |
| Net Income | $-457.98M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $2.27B |
| EPS (TTM) | $-1.77 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.89B |
| Sales | $885.72M |
| Income | $-457.98M |
| Book/sh | $-2.18 |
| Cash/sh | $0.94 |
| Employees | 435 |
Financial Ratios
| Quick Ratio | 1.78 |
| Current Ratio | 1.91 |
Returns & Margins
| ROA | 42.62% |
| Gross Margin | 76.63% |
| Operating Margin | -2.45% |
| Profit Margin | -51.71% |
Ownership
| Insider Ownership | 1.15% |
| Institutional Ownership | 101.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 13.16 |
| PEG | 9.39 |
| P/S | 2.57 |
| P/B | -4.11 |
Analyst Data
| Recommendation | none |
| Target Price | $21.30 |
Technical Indicators
| SMA20 | $8.61 |
| SMA50 | $8.93 |
| SMA200 | $7.93 |
| RSI | 46.91 |
| ATR | 0.3336 |
| Shares Float | 220.83M |
| Short Float | 14.53% |
| Short Ratio | 7.44 |
| Volatility | 0.56 |
| Rel Volume | 1.18 |
Performance History
| Week | +9.28% |
| Month | -0.22% |
| Quarter | -2.29% |
| 6 Months | +17.92% |
| YTD | +19.33% |
| Year | -13.02% |
| 3 Years | +7.83% |
| 5 Years | -48.00% |
| 10 Years | +214.04% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $8.95 | 4,450,600 |
| 2026-06-16 | $8.92 | 3,575,100 |
| 2026-06-15 | $9.06 | 4,153,900 |
| 2026-06-12 | $8.70 | 2,394,500 |
| 2026-06-11 | $8.50 | 3,820,200 |
| 2026-06-10 | $8.19 | 3,652,300 |
| 2026-06-09 | $8.33 | 3,797,900 |
| 2026-06-08 | $8.43 | 4,086,000 |
| 2026-06-05 | $8.41 | 2,500,800 |
| 2026-06-04 | $8.47 | 3,465,400 |
| 2026-06-03 | $8.25 | 4,229,700 |
| 2026-06-02 | $8.34 | 4,511,000 |
| 2026-06-01 | $8.57 | 3,084,300 |
| 2026-05-29 | $8.91 | 3,232,100 |
| 2026-05-28 | $9.10 | 3,349,300 |
| 2026-05-27 | $9.12 | 6,574,800 |
| 2026-05-26 | $8.47 | 4,013,200 |
| 2026-05-22 | $8.29 | 4,165,100 |
| 2026-05-21 | $8.37 | 4,051,700 |
| 2026-05-20 | $8.74 | 2,574,900 |
| 2026-05-19 | $8.77 | 3,876,300 |
| 2026-05-18 | $8.97 | 3,797,400 |
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
đ° Latest News
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-11T20:31:28Z
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
MarketBeat âĸ 2026-06-06T07:12:41Z
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?
Simply Wall St. âĸ 2026-05-12T16:18:03Z
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Q1 Results And Navenibart Licensing Deal
Simply Wall St. âĸ 2026-05-12T07:10:56Z
BioCryst (BCRX) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-06T19:11:37Z
BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-06T16:48:13Z
BioCryst Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-06T14:55:06Z
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-06T13:30:02Z
Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains
Simply Wall St. âĸ 2026-05-03T18:08:01Z
RBC Capital Lifts PT BioCryst Pharmaceuticals (BCRX) as Part of Q1 2026 Results Preview in Biotech
Insider Monkey âĸ 2026-05-01T07:58:10Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $19,075,000 | $12,269,000 | $4,481,000 | $6,594,000 |
| Cost Of Revenue | $19,075,000 | $12,269,000 | $4,481,000 | $6,594,000 |
| Total Revenue | $874,837,000 | $450,712,000 | $331,412,000 | $270,827,000 |
| Operating Revenue | $874,837,000 | $450,712,000 | $331,412,000 | $270,827,000 |
| Expenses | ||||
| Interest Expense | $78,872,000 | $98,516,000 | $108,239,000 | $99,092,000 |
| Total Expenses | $533,848,000 | $453,255,000 | $435,121,000 | $419,262,000 |
| Other Income Expense | $-5,394,000 | $-641,000 | $-30,058,000 | $-1,983,000 |
| Other Non Operating Income Expenses | $12,090,000 | - | - | - |
| Net Non Operating Interest Income Expense | $-68,204,000 | $-83,770,000 | $-92,462,000 | $-93,965,000 |
| Interest Expense Non Operating | $78,872,000 | $98,516,000 | $108,239,000 | $99,092,000 |
| Operating Expense | $514,773,000 | $440,986,000 | $430,640,000 | $412,668,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Net Interest Income | $-68,204,000 | $-83,770,000 | $-92,462,000 | $-93,965,000 |
| Interest Income | $10,668,000 | $14,746,000 | $15,777,000 | $5,127,000 |
| Normalized Income | $281,170,160 | $-88,374,610 | $-202,793,180 | $-245,549,430 |
| Net Income From Continuing And Discontinued Operation | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Total Operating Income As Reported | $340,989,000 | $-2,543,000 | $-103,709,000 | $-148,435,000 |
| Net Income Common Stockholders | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Net Income | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Net Income Including Noncontrolling Interests | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Net Income Continuous Operations | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Pretax Income | $267,391,000 | $-86,954,000 | $-226,229,000 | $-244,383,000 |
| Special Income Charges | $-17,332,000 | $0 | $-29,019,000 | $0 |
| Interest Income Non Operating | $10,668,000 | $14,746,000 | $15,777,000 | $5,127,000 |
| Operating Income | $340,989,000 | $-2,543,000 | $-103,709,000 | $-148,435,000 |
| Gross Profit | $855,762,000 | $438,443,000 | $326,931,000 | $264,233,000 |
| Per Share | ||||
| Diluted EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 |
| Basic EPS | $1.26 | $-0.43 | $-1.18 | $-1.33 |
| Other | ||||
| Tax Effect Of Unusual Items | $-174,840 | $-134,610 | $-6,312,180 | $-416,430 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $365,136,000 | $13,449,000 | $-86,277,000 | $-141,871,000 |
| Total Unusual Items | $-17,484,000 | $-641,000 | $-30,058,000 | $-1,983,000 |
| Total Unusual Items Excluding Goodwill | $-17,484,000 | $-641,000 | $-30,058,000 | $-1,983,000 |
| Reconciled Depreciation | $1,389,000 | $1,246,000 | $1,655,000 | $1,437,000 |
| EBITDA (Bullshit earnings) | $347,652,000 | $12,808,000 | $-116,335,000 | $-143,854,000 |
| EBIT | $346,263,000 | $11,562,000 | $-117,990,000 | $-145,291,000 |
| Diluted Average Shares | $218,581,000 | $206,696,000 | $192,198,000 | $185,908,000 |
| Basic Average Shares | $209,893,000 | $206,696,000 | $192,198,000 | $185,908,000 |
| Diluted NI Availto Com Stockholders | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Tax Provision | $3,530,000 | $1,927,000 | $310,000 | $2,733,000 |
| Other Special Charges | $17,332,000 | - | $29,019,000 | - |
| Gain On Sale Of Security | $-152,000 | $-641,000 | $-1,039,000 | $-1,983,000 |
| Research And Development | $166,126,000 | $174,638,000 | $216,566,000 | $253,297,000 |
| Selling General And Administration | $348,647,000 | $266,348,000 | $214,074,000 | $159,371,000 |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-119,153,000 | $-475,934,000 | $-455,528,000 | $-294,597,000 |
| Total Assets | $514,158,000 | $490,420,000 | $516,960,000 | $550,000,000 |
| Total Non Current Assets | $109,812,000 | $68,452,000 | $20,994,000 | $33,500,000 |
| Other Non Current Assets | $29,662,000 | $28,344,000 | $80,000 | $6,806,000 |
| Current Assets | $404,346,000 | $421,968,000 | $495,966,000 | $516,500,000 |
| Other Current Assets | $17,182,000 | $13,752,000 | $19,542,000 | $12,586,000 |
| Restricted Cash | $201,000 | $210,000 | $1,804,000 | $1,472,000 |
| Inventory | $5,398,000 | $8,087,000 | $28,683,000 | $27,533,000 |
| Receivables | $106,818,000 | $79,069,000 | $56,950,000 | $50,599,000 |
| Accounts Receivable | $106,818,000 | $79,069,000 | $56,950,000 | $50,599,000 |
| Cash Cash Equivalents And Short Term Investments | $274,747,000 | $320,850,000 | $388,987,000 | $424,310,000 |
| Cash And Cash Equivalents | $89,736,000 | $104,713,000 | $110,643,000 | $304,767,000 |
| Investmentin Financial Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $337,497,000 | $691,209,000 | $700,622,000 | $428,512,000 |
| Total Debt | $438,874,000 | $808,742,000 | $825,148,000 | $741,452,000 |
| Long Term Debt And Capital Lease Obligation | $437,245,000 | $805,970,000 | $822,500,000 | $739,083,000 |
| Long Term Debt | $427,233,000 | $795,922,000 | $811,265,000 | $733,279,000 |
| Current Debt And Capital Lease Obligation | $1,629,000 | $2,772,000 | $2,648,000 | $2,369,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $633,311,000 | $966,354,000 | $972,488,000 | $844,597,000 |
| Total Non Current Liabilities Net Minority Interest | $437,245,000 | $805,970,000 | $822,500,000 | $739,083,000 |
| Current Liabilities | $196,066,000 | $160,384,000 | $149,988,000 | $105,514,000 |
| Other Current Liabilities | $52,198,000 | $32,676,000 | $23,565,000 | - |
| Payables And Accrued Expenses | $64,750,000 | $44,189,000 | $60,748,000 | $65,464,000 |
| Payables | $24,786,000 | $26,234,000 | $39,417,000 | $22,056,000 |
| Other Payable | $8,960,000 | $14,590,000 | $18,524,000 | $7,700,000 |
| Accounts Payable | $15,826,000 | $11,644,000 | $20,893,000 | $14,356,000 |
| Current Deferred Liabilities | - | - | $0 | $1,224,000 |
| Total Tax Payable | - | - | - | $410,000 |
| Equity | ||||
| Common Stock Equity | $-119,153,000 | $-475,934,000 | $-455,528,000 | $-294,597,000 |
| Total Equity Gross Minority Interest | $-119,153,000 | $-475,934,000 | $-455,528,000 | $-294,597,000 |
| Stockholders Equity | $-119,153,000 | $-475,934,000 | $-455,528,000 | $-294,597,000 |
| Gains Losses Not Affecting Retained Earnings | $38,000 | $921,000 | $1,337,000 | $26,000 |
| Other Equity Adjustments | $38,000 | $921,000 | $1,337,000 | $26,000 |
| Retained Earnings | $-1,506,179,000 | $-1,770,040,000 | $-1,681,159,000 | $-1,454,620,000 |
| Other | ||||
| Ordinary Shares Number | $213,059,576 | $208,543,452 | $205,771,000 | $187,906,000 |
| Share Issued | $213,059,576 | $208,543,452 | $205,771,000 | $187,906,000 |
| Tangible Book Value | $-119,153,000 | $-475,934,000 | $-455,528,000 | $-294,597,000 |
| Invested Capital | $308,080,000 | $319,988,000 | $355,737,000 | $438,682,000 |
| Working Capital | $208,280,000 | $261,584,000 | $345,978,000 | $410,986,000 |
| Capital Lease Obligations | $11,641,000 | $12,820,000 | $13,883,000 | $8,173,000 |
| Total Capitalization | $308,080,000 | $319,988,000 | $355,737,000 | $438,682,000 |
| Additional Paid In Capital | $1,384,857,000 | $1,291,100,000 | $1,222,236,000 | $1,158,118,000 |
| Capital Stock | $2,131,000 | $2,085,000 | $2,058,000 | $1,879,000 |
| Common Stock | $2,131,000 | $2,085,000 | $2,058,000 | $1,879,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $10,012,000 | $10,048,000 | $11,235,000 | $5,804,000 |
| Current Capital Lease Obligation | $1,629,000 | $2,772,000 | $2,648,000 | $2,369,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $50,857,000 | $48,631,000 | $36,518,000 | $22,125,000 |
| Current Provisions | $26,632,000 | $32,116,000 | $26,509,000 | $14,332,000 |
| Current Accrued Expenses | $39,964,000 | $17,955,000 | $21,331,000 | $43,408,000 |
| Investments And Advances | $61,164,000 | $20,323,000 | $0 | $18,077,000 |
| Net PPE | $18,986,000 | $19,785,000 | $20,914,000 | $8,617,000 |
| Accumulated Depreciation | $-9,394,000 | $-12,349,000 | $-11,210,000 | $-9,550,000 |
| Gross PPE | $28,380,000 | $32,134,000 | $32,124,000 | $18,167,000 |
| Leases | $10,437,000 | $10,363,000 | $10,206,000 | $10,137,000 |
| Construction In Progress | $0 | $97,000 | $0 | - |
| Other Properties | $15,796,000 | $18,230,000 | $18,563,000 | $4,588,000 |
| Machinery Furniture Equipment | $2,147,000 | $3,444,000 | $3,355,000 | $3,442,000 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-775,000 | $-2,649,000 | $-1,599,000 | $-1,177,000 |
| Other Inventories | $-23,990,000 | $-23,187,000 | - | - |
| Finished Goods | $7,275,000 | $7,765,000 | $6,242,000 | $4,814,000 |
| Work In Process | $12,891,000 | $16,152,000 | $17,591,000 | $14,990,000 |
| Raw Materials | $9,997,000 | $10,006,000 | $6,449,000 | $8,906,000 |
| Other Short Term Investments | $185,011,000 | $216,137,000 | $278,344,000 | $119,543,000 |
| Treasury Shares Number | - | - | $0 | - |
| Current Deferred Revenue | - | - | $0 | $1,224,000 |
| Available For Sale Securities | - | - | - | - |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $344,901,000 | $-53,144,000 | $-97,309,000 | $-163,201,000 |
| Operating Activities | ||||
| Operating Cash Flow | $347,369,000 | $-52,020,000 | $-95,141,000 | $-161,850,000 |
| Cash Flow From Continuing Operating Activities | $347,369,000 | $-52,020,000 | $-95,141,000 | $-161,850,000 |
| Operating Gains Losses | $26,451,000 | - | $29,019,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-2,468,000 | $-1,124,000 | $-2,168,000 | $-1,351,000 |
| Investing Cash Flow | $-13,694,000 | $52,593,000 | $-131,498,000 | $-128,238,000 |
| Cash Flow From Continuing Investing Activities | $-13,694,000 | $52,593,000 | $-131,498,000 | $-128,238,000 |
| Net Other Investing Changes | $550,000 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $59,000 | $34,000 | $342,000 | $190,000 |
| Financing Cash Flow | $-349,931,000 | $-5,761,000 | $32,485,000 | $88,027,000 |
| Cash Flow From Continuing Financing Activities | $-349,931,000 | $-5,761,000 | $32,485,000 | $88,027,000 |
| Net Other Financing Charges | $-57,116,000 | $-7,535,000 | $-34,580,000 | - |
| Net Common Stock Issuance | $59,000 | $34,000 | $342,000 | $190,000 |
| Common Stock Issuance | $59,000 | $34,000 | $342,000 | $190,000 |
| Other | ||||
| Repayment Of Debt | $-301,989,000 | $-1,704,000 | $-241,617,000 | $0 |
| Issuance Of Debt | $0 | $0 | $300,000,000 | $73,072,000 |
| Interest Paid Supplemental Data | $23,735,000 | $30,383,000 | $22,139,000 | $0 |
| End Cash Position | $91,337,000 | $106,323,000 | $112,447,000 | $306,239,000 |
| Beginning Cash Position | $106,323,000 | $112,447,000 | $306,239,000 | $507,734,000 |
| Effect Of Exchange Rate Changes | $1,270,000 | $-936,000 | $362,000 | $566,000 |
| Changes In Cash | $-16,256,000 | $-5,188,000 | $-194,154,000 | $-202,061,000 |
| Proceeds From Stock Option Exercised | $9,115,000 | $3,444,000 | $8,340,000 | $14,765,000 |
| Net Issuance Payments Of Debt | $-301,989,000 | $-1,704,000 | $58,383,000 | $73,072,000 |
| Net Long Term Debt Issuance | $-301,989,000 | $-1,704,000 | $58,383,000 | $73,072,000 |
| Long Term Debt Payments | $-301,989,000 | $-1,704,000 | $-241,617,000 | $0 |
| Long Term Debt Issuance | $0 | $0 | $300,000,000 | $73,072,000 |
| Net Investment Purchase And Sale | $-5,593,000 | $53,717,000 | $-129,330,000 | $-126,887,000 |
| Sale Of Investment | $256,647,000 | $320,480,000 | $385,077,000 | $117,396,000 |
| Purchase Of Investment | $-262,240,000 | $-266,763,000 | $-514,407,000 | $-244,283,000 |
| Net Business Purchase And Sale | $-6,183,000 | $0 | $0 | - |
| Purchase Of Business | $-6,183,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-2,468,000 | $-1,124,000 | $-2,168,000 | $-1,351,000 |
| Purchase Of PPE | $-2,468,000 | $-1,124,000 | $-2,168,000 | $-1,351,000 |
| Change In Working Capital | $-56,898,000 | $-87,282,000 | $-32,401,000 | $-58,945,000 |
| Change In Other Current Liabilities | $-68,428,000 | $-77,155,000 | $-29,337,000 | - |
| Change In Payables And Accrued Expense | $57,802,000 | $14,776,000 | $12,531,000 | $-22,360,000 |
| Change In Payable | $57,802,000 | $14,776,000 | $12,531,000 | $-22,360,000 |
| Change In Account Payable | $57,802,000 | $14,776,000 | $12,531,000 | $-22,360,000 |
| Change In Prepaid Assets | $-7,827,000 | $1,959,000 | $-6,820,000 | $-2,583,000 |
| Change In Inventory | $-1,639,000 | $-4,164,000 | $-1,450,000 | $-12,423,000 |
| Change In Receivables | $-36,806,000 | $-22,698,000 | $-6,095,000 | $-21,470,000 |
| Other Non Cash Items | $30,846,000 | $67,607,000 | $85,803,000 | $98,918,000 |
| Stock Based Compensation | $85,066,000 | $65,413,000 | $55,615,000 | $44,701,000 |
| Asset Impairment Charge | $985,000 | $1,350,000 | $1,970,000 | $932,000 |
| Amortization Of Securities | $-4,331,000 | $-11,473,000 | $-10,263,000 | $-1,777,000 |
| Depreciation Amortization Depletion | $1,389,000 | $1,246,000 | $1,655,000 | $1,437,000 |
| Depreciation And Amortization | $1,389,000 | $1,246,000 | $1,655,000 | $1,437,000 |
| Depreciation | $1,389,000 | $1,246,000 | $1,655,000 | $1,437,000 |
| Earnings Losses From Equity Investments | $17,548,000 | $0 | $0 | - |
| Gain Loss On Investment Securities | $-4,863,000 | - | - | - |
| Gain Loss On Sale Of Business | $-3,566,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $263,861,000 | $-88,881,000 | $-226,539,000 | $-247,116,000 |
| Income Tax Paid Supplemental Data | - | $1,603,000 | $1,434,000 | $3,542,000 |
| Change In Other Working Capital | - | - | $-1,230,000 | $-109,000 |
| Change In Accrued Expense | - | - | $0 | $0 |
| Change In Interest Payable | - | - | $0 | $0 |
| Net Short Term Debt Issuance | - | - | - | $73,072,000 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $73,072,000 |
Fetched: 2026-06-11